The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets, , on November 15, 2020 at 3:09 pm

By
On November 15, 2020
Tags:

Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.The week started with positive tidings from Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE – ADR (NASDAQ: BNTX), which reported positive interim Phase 3 data for their jointly developed mRNA vaccine against the COVID-19 coronavirus.An update from rival vaccine developer Moderna Inc (NASDAQ: MRNA) on reaching the mandated number of cases for its first interim analysis also generated optimism.Five Prime Therapeutics Inc (NASDAQ: FPRX) rallied over 300% during the week, with the upside primarily due to a positive mid-stage readout for its investigational drug in a stomach cancer study.Supernus Pharmaceuticals Inc (NASDAQ: SUPN), meanwhile, came under pressure after the FDA rejected its ADHD drug.Earnings news flow continued, but the week was silent on the IPO front. Multiple conferences got underway during the week, giving biopharma companies a chance to show new data on products they’re investigating.Here are the key catalysts for the week from Nov. 13.Conferences * American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov. 13-15 * American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting, Digital Experience: Nov. 13-16 * Guggenheim Healthcare Talks, Idea Forum, 2nd Annual Neuro/Immunology Day: Nov. 16 * Stifel 2020 Virtual Healthcare Conference: Nov. 16-18 * Jefferies Virtual London Healthcare Conference: Nov. 17-19 * Wolfe Research Virtual Healthcare Conference: Nov. 18-19 * Connective Tissue Oncology Society, or CTOS, Virtual Annual Meeting: Nov. 18-21 * SVB Leerink Oncology Day: Nov. 19 * 2020 Society for Neuro-Oncology, or SNO, Virtual Meeting: Nov. 19-21PDUFA Dates The FDA is set to rule on Alkermes Plc’s (NASDAQ: ALKS) NDA for ALKS 3831 in schizophrenia and bipolar I disorder. (Sunday)Also on Sunday, the fate of Adamis Pharmaceuticals Corp’s (NASDAQ: ADMP) Zimhi, an investigational treatment for opioid overdose, is to be decided by the FDA.Mylan NV (NASDAQ: MYL) awaits the FDA’s nod for its ANDA for dimethyl fumarate, a generic version of one made by Biogen Inc (NASDAQ: BIIB) to treat a relapsing form of multiple sclerosis. (Monday)The FDA has set a PDUFA date of Nov. 16 for Bristol-Myers Squibb Co’s (NYSE: BMY) BLA for liso-cel as a treatment option for patients with relapsed or refractory large B-cell lymphoma after at least two prior therapies. (Monday)Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) awaits a decisive moment with the FDA on Nov. 20 with respect to its NDA for Lonfarnib in progeria and progeroid laminopathies. (Friday)Clinical Readout/Data Presentations AAO Meeting Presentations Lineage Cell Therapeutics Inc (NYSE: LCTX): updated interim results from the ongoing Phase 1/2a study of its lead product candidate OpRegen in dry age-related macular degeneration. (Sunday); the company has also scheduled a call with key opinion leaders Tuesday, 4 pm ET, to discuss the data.AASLD Presentations Albireo Pharma Inc (NASDAQ: ALBO): new data from a Phase 3 study of odevixibat in progressive familial intrahepatic cholestasis (Sunday)Inventiva ADR Representing Ord Shs (NASDAQ: IVA): new data from the NATIVE Phase 2b clinical trial evaluating lanifibranor for NASH, focusing on the efficacy of lanifibranor in type-2 diabetic patients and its positive effect on key plasma biomarkers (Sunday)Akero Therapeutics Inc (NASDAQ: AKRO): additional data analysis from the Phase 2a BALANCED study of efruxifermin in non-alcoholic steatohepatitis (Sunday)Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): Updated Phase 1 data for RG6346 in HBV infection (Monday)CymaBay Therapeutics Inc (NASDAQ: CBAY): a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (Monday)Related Link: 7 Stocks That Could Benefit From Pfizer’s COVID-19 Vaccine That Requires Cold Chain Storage SNO Meeting Presentations VBI Vaccines Inc (NASDAQ: VBIV): data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (Thursday)Kintara Therapeutics Inc (NASDAQ: KTRA): update on Phase 2 studies of VAL-083 in MGMT-unmethylated Recurrent Glioblastoma Multiforme (Thursday)Plus Therapeutics Inc (NASDAQ: PSTV): new interim data from the ongoing NIH-sponsored ReSPECT Phase 1 clinical trial evaluating its lead investigational asset, Rhenium NanoLiposome in patients with recurrent glioblastoma (Thursday)CTOS Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsStandalone Data Readouts Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day scheduled for Tuesday additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.Pfizer and BioNTech expect safety data milestone to be achieved in the third week of November and plan for emergency use authorization shortly after.Moderna could release interim Phase 3 readout for its coronavirus vaccine candidate, given it has said it has reached the mandated number of cases for analysis.Earnings Monday Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) Jaguar Health Inc (NASDAQ: JAGX) (before the market open) Celsion Corporation (NASDAQ: CLSN) (before the market open)Tuesday Trinity Biotech plc (NASDAQ: TRIB) (before the market open) PAVmed Inc (NASDAQ: PAVM)Wednesday Edap Tms SA (NASDAQ: EDAP) (after the close)Thursday Precipio Inc (NASDAQ: PRPO) (after the close)Friday Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. is planning to sell in an initial public offering 50 million shares of its common stock at a price range of $24-$27. The company, which provides critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases, said its shares will be listed on the Nasdaq under the ticker symbol MRVI.Sotera Health Company,, a sterilization, lab testing and advisory services company, has filed a prospectus with the SEC to offer 46.6 million shares of its common stock, which are to be priced between $20 and $23. The Broadview Heights, Ohio-based company has applied for listing its shares on the Nasdaq under the ticker symbol SHC.IPO Quiet Period Expiry Foghorn Therapeutics Inc. (NASDAQ: FHTX)See more from Benzinga * Click here for options trades from Benzinga * Moderna Achieves COVID-19 Case Number For First Interim Readout: What’s Next? * What Pfizer’s Coronavirus Vaccine Data Means For Moderna(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.,

The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The MarketsBiotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.The week started with positive tidings from Pfizer Inc. (NYSE: PFE) and its German partner BioNTech SE – ADR (NASDAQ: BNTX), which reported positive interim Phase 3 data for their jointly developed mRNA vaccine against the COVID-19 coronavirus.An update from rival vaccine developer Moderna Inc (NASDAQ: MRNA) on reaching the mandated number of cases for its first interim analysis also generated optimism.Five Prime Therapeutics Inc (NASDAQ: FPRX) rallied over 300% during the week, with the upside primarily due to a positive mid-stage readout for its investigational drug in a stomach cancer study.Supernus Pharmaceuticals Inc (NASDAQ: SUPN), meanwhile, came under pressure after the FDA rejected its ADHD drug.Earnings news flow continued, but the week was silent on the IPO front. Multiple conferences got underway during the week, giving biopharma companies a chance to show new data on products they’re investigating.Here are the key catalysts for the week from Nov. 13.Conferences * American Academy of Ophthalmology, or AAO, 2020 Virtual meeting: Nov. 13-15 * American Association for the Study of Liver Diseases, or AASLD, The Liver Meeting, Digital Experience: Nov. 13-16 * Guggenheim Healthcare Talks, Idea Forum, 2nd Annual Neuro/Immunology Day: Nov. 16 * Stifel 2020 Virtual Healthcare Conference: Nov. 16-18 * Jefferies Virtual London Healthcare Conference: Nov. 17-19 * Wolfe Research Virtual Healthcare Conference: Nov. 18-19 * Connective Tissue Oncology Society, or CTOS, Virtual Annual Meeting: Nov. 18-21 * SVB Leerink Oncology Day: Nov. 19 * 2020 Society for Neuro-Oncology, or SNO, Virtual Meeting: Nov. 19-21PDUFA Dates The FDA is set to rule on Alkermes Plc’s (NASDAQ: ALKS) NDA for ALKS 3831 in schizophrenia and bipolar I disorder. (Sunday)Also on Sunday, the fate of Adamis Pharmaceuticals Corp’s (NASDAQ: ADMP) Zimhi, an investigational treatment for opioid overdose, is to be decided by the FDA.Mylan NV (NASDAQ: MYL) awaits the FDA’s nod for its ANDA for dimethyl fumarate, a generic version of one made by Biogen Inc (NASDAQ: BIIB) to treat a relapsing form of multiple sclerosis. (Monday)The FDA has set a PDUFA date of Nov. 16 for Bristol-Myers Squibb Co’s (NYSE: BMY) BLA for liso-cel as a treatment option for patients with relapsed or refractory large B-cell lymphoma after at least two prior therapies. (Monday)Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) awaits a decisive moment with the FDA on Nov. 20 with respect to its NDA for Lonfarnib in progeria and progeroid laminopathies. (Friday)Clinical Readout/Data Presentations AAO Meeting Presentations Lineage Cell Therapeutics Inc (NYSE: LCTX): updated interim results from the ongoing Phase 1/2a study of its lead product candidate OpRegen in dry age-related macular degeneration. (Sunday); the company has also scheduled a call with key opinion leaders Tuesday, 4 pm ET, to discuss the data.AASLD Presentations Albireo Pharma Inc (NASDAQ: ALBO): new data from a Phase 3 study of odevixibat in progressive familial intrahepatic cholestasis (Sunday)Inventiva ADR Representing Ord Shs (NASDAQ: IVA): new data from the NATIVE Phase 2b clinical trial evaluating lanifibranor for NASH, focusing on the efficacy of lanifibranor in type-2 diabetic patients and its positive effect on key plasma biomarkers (Sunday)Akero Therapeutics Inc (NASDAQ: AKRO): additional data analysis from the Phase 2a BALANCED study of efruxifermin in non-alcoholic steatohepatitis (Sunday)Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): Updated Phase 1 data for RG6346 in HBV infection (Monday)CymaBay Therapeutics Inc (NASDAQ: CBAY): a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (Monday)Related Link: 7 Stocks That Could Benefit From Pfizer’s COVID-19 Vaccine That Requires Cold Chain Storage SNO Meeting Presentations VBI Vaccines Inc (NASDAQ: VBIV): data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (Thursday)Kintara Therapeutics Inc (NASDAQ: KTRA): update on Phase 2 studies of VAL-083 in MGMT-unmethylated Recurrent Glioblastoma Multiforme (Thursday)Plus Therapeutics Inc (NASDAQ: PSTV): new interim data from the ongoing NIH-sponsored ReSPECT Phase 1 clinical trial evaluating its lead investigational asset, Rhenium NanoLiposome in patients with recurrent glioblastoma (Thursday)CTOS Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsStandalone Data Readouts Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day scheduled for Tuesday additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.Pfizer and BioNTech expect safety data milestone to be achieved in the third week of November and plan for emergency use authorization shortly after.Moderna could release interim Phase 3 readout for its coronavirus vaccine candidate, given it has said it has reached the mandated number of cases for analysis.Earnings Monday Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) Jaguar Health Inc (NASDAQ: JAGX) (before the market open) Celsion Corporation (NASDAQ: CLSN) (before the market open)Tuesday Trinity Biotech plc (NASDAQ: TRIB) (before the market open) PAVmed Inc (NASDAQ: PAVM)Wednesday Edap Tms SA (NASDAQ: EDAP) (after the close)Thursday Precipio Inc (NASDAQ: PRPO) (after the close)Friday Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. is planning to sell in an initial public offering 50 million shares of its common stock at a price range of $24-$27. The company, which provides critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases, said its shares will be listed on the Nasdaq under the ticker symbol MRVI.Sotera Health Company,, a sterilization, lab testing and advisory services company, has filed a prospectus with the SEC to offer 46.6 million shares of its common stock, which are to be priced between $20 and $23. The Broadview Heights, Ohio-based company has applied for listing its shares on the Nasdaq under the ticker symbol SHC.IPO Quiet Period Expiry Foghorn Therapeutics Inc. (NASDAQ: FHTX)See more from Benzinga * Click here for options trades from Benzinga * Moderna Achieves COVID-19 Case Number For First Interim Readout: What’s Next? * What Pfizer’s Coronavirus Vaccine Data Means For Moderna(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road
#12-01 Capital Tower
Singapore 068912

New York

Coming Soon!

Dubai

Coming Soon!

Market Coverage